We are live on ! Find out more
OTLK icon

Outlook Therapeutics

63 hedge funds and large institutions have $50.4M invested in Outlook Therapeutics in 2021 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

307% more capital inflows, than outflows

Capital inflows: $21M | Capital outflows: $5.16M

100% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 14

29% more funds holding

Funds holding: 49 → 63 (+14)

3.9% more ownership

Funds ownership: 7.77% → 11.66% (+3.9%)

27% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 15

Holders
63
Holders Change
+14
Holders Change %
+28.57%
% of All Funds
1.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
11
Reduced
15
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

OTLK Hedge Fund Activity: Q2 2021 in Review

63 of the 5,771 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2021, worth a combined $50.4M — up 66% from $30.3M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new OTLK positions and 14 closed out — a net gain of 14 holders — while 11 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $9.3M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.87M sold.

  • 63 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2021, up from 49 in Q1 2021.
  • Funds reported $50.4M of Outlook Therapeutics stock for Q2 2021, up 66% quarter-over-quarter.
  • 28 funds opened new Outlook Therapeutics positions in Q2 2021 and 14 closed out, a net change of +14 holders.
  • The largest Outlook Therapeutics buyer in Q2 2021 was BlackRock, an estimated $9.3M added.
  • The largest Outlook Therapeutics seller in Q2 2021 was Renaissance Technologies, an estimated $1.87M sold.

Based on aggregated 13F filings for Q2 2021.